Group 1 - The company announced that its Vice President, Li Xianlin, has submitted a written resignation due to reaching retirement age [1] - Li Xianlin will resign from his position as Vice President and from all other roles within the company and its subsidiaries [1]

证券代码：600420 证券简称：国药现代 公告编号：2025-060 二、离任对公司的影响 根据《中华人民共和国公司法》和《公司章程》等相关规定，李显林先生的 辞职报告自送达公司董事会之日起生效，李显林先生离任后将不在公司及所属子 公司担任任何职务。上述事项对公司正常的生产经营不会产生影响。 特此公告。 上海现代制药股份有限公司董事会 上海现代制药股份有限公司 关于高级管理人员离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海现代制药股份有限公司（以下简称公司）董事会近日收到公司副总裁李 显林先生的书面辞职申请。李显林先生由于达到退休年龄，申请辞去公司副总裁 及在公司和所属子公司兼任的其他所有职务，具体情况如下。 | 姓名 | 离任职务 | 离任时间 | | 原定任期 | | | 是否继续在上 | 是否存在未 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 到期日 | | 离任原因 | 市公司及其控 | 履行完毕的 | | ...

Group 1 - The core stock price of Guoyao Modern (600420) closed at 11.39 yuan, up 2.06% from last week's 11.16 yuan, with a market cap of 15.276 billion yuan [1] - The highest intraday price reached 11.8 yuan on July 31, while the lowest was 11.12 yuan on July 29 [1] - Guoyao Modern ranks 39th out of 150 in the chemical pharmaceutical sector and 1117th out of 5149 in the A-share market [1] Group 2 - Guoyao Modern plans to publicly transfer 51% of its stake in Guoyao Harsen at a base price of 155.192541 million yuan [1] - The transaction aims to optimize resource allocation and improve asset operation efficiency [1] - Guoyao Harsen, established in November 1999, has total assets of 339.1778 million yuan and total liabilities of 187.15 million yuan as of April 30, 2025 [1] Group 3 - For the first four months of 2025, Guoyao Harsen reported revenue of 100.7613 million yuan and a net loss of 19.898 million yuan [1] - The assessed value of the shareholders' equity in Guoyao Harsen is 304.2991 million yuan, with an appreciation rate of 100.16% [1] - After the transfer, Guoyao Harsen will no longer be included in the consolidated financial statements of Guoyao Modern [1]

Group 1 - The core viewpoint of the news is that Guoyao Modern (600420) has experienced a decline in stock price and a significant net outflow of funds, despite a year-on-year increase in net profit for the first quarter of 2025 [1][3] - As of August 1, 2025, Guoyao Modern's stock closed at 11.39 yuan, down 0.7%, with a turnover rate of 1.79% and a trading volume of 240,300 hands, amounting to 276 million yuan [1] - The company's latest financial performance shows total operating revenue of 2.607 billion yuan for Q1 2025, a year-on-year decrease of 16.54%, while net profit attributable to shareholders was 361 million yuan, an increase of 9.10% [1] Group 2 - Guoyao Modern has a current liquidity ratio of 3.317, a quick ratio of 2.682, and a debt-to-asset ratio of 18.54%, indicating a strong liquidity position [1] - The company has made investments in 23 enterprises and participated in 5,000 bidding projects, showcasing its active engagement in the market [2] - Guoyao Modern holds 113 trademark registrations and 137 patents, along with 245 administrative licenses, reflecting its commitment to intellectual property and regulatory compliance [2]

Summary of Key Points Core Viewpoint - The company, Guoyao Modern, is undergoing a significant transaction involving the transfer of a 51% stake in Shanghai Modern Harsen Pharmaceutical Co., Ltd. The transaction is not classified as a major asset restructuring and is expected to impact the company's financial reporting structure post-completion [2][4]. Trading Information - As of July 31, 2025, Guoyao Modern's stock closed at 11.47 yuan, reflecting a decrease of 0.95%. The turnover rate was 2.33%, with a trading volume of 312,400 shares and a total transaction value of 361 million yuan [1]. - On the same day, the net outflow of main funds was 16.986 million yuan, accounting for 4.71% of the total transaction value. In contrast, retail funds saw a net inflow of 4.7 million yuan, representing 1.3% of the total transaction value [2][4]. Company Announcement - Guoyao Modern announced the public transfer of its 51% stake in Shanghai Modern Harsen Pharmaceutical Co., Ltd. at a base price of 155.192541 million yuan. The transaction does not constitute a major asset restructuring, and the details regarding the transaction counterpart, price, and timing are yet to be determined [2][4]. - As of April 30, 2025, Shanghai Modern Harsen reported total assets of 339.1778 million yuan, total liabilities of 187.15 million yuan, and owner’s equity of 152.0278 million yuan. The revenue for the first four months of 2025 was 100.7613 million yuan, with a net loss of 19.898 million yuan [2]. - The assessed value of the total equity of Shanghai Modern Harsen is 304.2991 million yuan, indicating a value increase of 100.16% [2].

Core Viewpoint - Shanghai Modern Pharmaceutical Co., Ltd. is publicly transferring 51% equity of its subsidiary, Shanghai Modern Harsen (Shangqiu) Pharmaceutical Co., Ltd., with a base price of RMB 155.192541 million, aiming to optimize resource allocation and improve operational efficiency [2][4]. Group 1: Transaction Overview - The company announced the public transfer of 51% equity of its subsidiary on July 30, 2025, with a base price set at RMB 155.192541 million [2][4]. - The transaction does not constitute a major asset restructuring and is not currently classified as a related party transaction [3][4]. - The transfer aims to enhance the company's strategic focus and asset efficiency, as the subsidiary has been underperforming since 2021 [12]. Group 2: Target Company Information - The target company, Shanghai Modern Harsen (Shangqiu) Pharmaceutical Co., Ltd., was established on November 12, 1999, with a registered capital of RMB 83.29 million [6]. - The company operates in the production and sales of pharmaceuticals, disinfectants, health foods, and other related products [7]. - As of April 30, 2025, the net assets of the target company were valued at RMB 152.0278 million, with a total equity valuation of RMB 304.2991 million, reflecting a 100.16% increase in value [9]. Group 3: Financial Impact and Future Steps - The completion of the equity transfer will result in the subsidiary no longer being included in the company's consolidated financial statements, potentially impacting the company's financial performance for 2025 [12]. - The specific details regarding the buyer and final transaction price remain undetermined, and the company will disclose further information as the transaction progresses [11][12].

证券代码：600420 证券简称：国药现代 公告编号：2025-059 上海现代制药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 上海现代制药股份有限公司（以下简称公司）于 2025 年 7 月 30 日在上 海联合产权交易所公开挂牌，转让所持有的上海现代哈森（商丘）药业有限公司 （以下简称国药哈森）51%股权，挂牌底价为人民币 15,519.2541 万元。 ? 本次交易不构成重大资产重组。 ? 本次交易的交易对象、交易价格和交易时间尚未确定，交易成功与否尚 存在不确定性，目前暂不构成关联交易。公司将根据本次交易的后续进展情况， 按照有关规定及时履行信息披露义务，敬请广大投资者注意投资风险。 一、交易概述 提示性公告》，为推进实施公司中长期战略规划，优化资源配置，提高公司资产 的运营效率，公司拟公开挂牌转让控股子公司国药哈森 51%股权（详见公司 药哈森 51%股权，挂牌底价为人民币 15,519.2541 万元。 上述事项已经公司总裁办公会审议通过，并已获得中国医药集团有限公司批 复。根 ...

（文章来源：证券日报） 证券日报网讯 7月30日晚间，国药现代发布公告称，公司于2025年7月30日在上海联合产权交易所公开 挂牌，转让所持有的上海现代哈森（商丘）药业有限公司（简称"国药哈森"）51%股权，挂牌底价为人 民币15，519.2541万元。上述事项已经公司总裁办公会审议通过，并已获得中国医药集团有限公司批 复。根据《上海证券交易所股票上市规则》及公司《章程》，该事项目前无需提交董事会审议。 ...

证券代码：600420 证券简称：国药现代 公告编号：2025-059 上海现代制药股份有限公司 关于公开挂牌转让控股子公司股权的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海现代制药股份有限公司（以下简称公司）于 2025 年 7 月 30 日在上 海联合产权交易所公开挂牌，转让所持有的上海现代哈森（商丘）药业有限公司 （以下简称国药哈森）51%股权，挂牌底价为人民币 15,519.2541 万元。 本次交易不构成重大资产重组。 本次交易的交易对象、交易价格和交易时间尚未确定，交易成功与否尚 存在不确定性，目前暂不构成关联交易。公司将根据本次交易的后续进展情况， 按照有关规定及时履行信息披露义务，敬请广大投资者注意投资风险。 一、交易概述 2025 年 7 月 1 日，公司披露了《关于拟公开转让控股子公司股权预挂牌的 提示性公告》，为推进实施公司中长期战略规划，优化资源配置，提高公司资产 的运营效率，公司拟公开挂牌转让控股子公司国药哈森 51%股权（详见公司 2025-55 号公告）。 202 ...

金融界消息 截至2025年7月29日收盘，国药现代（600420）报收于11.36元，上涨1.07%，换手率 1.45%，成交量19.49万手，成交金额2.20亿元。 资金流向方面，今日主力资金净流入1962.14万元，占比成交额8.91%。其中，超大单净流入520.72万 元、占成交额2.36%，大单净流入1441.42万元、占成交额6.54%，中单净流出流入217.09万元、占成交 额0.99%，小单净流出2179.23万元、占成交额9.89%。 通过天眼查大数据分析，上海现代制药股份有限公司共对外投资了23家企业，参与招投标项目5000次， 知识产权方面有商标信息113条，专利信息137条，此外企业还拥有行政许可245个。 来源：金融界 国药现代最新一期业绩显示，截至2025一季报，公司营业总收入26.07亿元、同比减少16.54%，归属净 利润3.61亿元，同比增长9.10%，扣非净利润3.46亿元，同比增长6.24%，流动比率3.317、速动比率 2.682、资产负债率18.54%。 天眼查商业履历信息显示，上海现代制药股份有限公司，成立于1996年，位于上海市，是一家以从事医 药制造业为主的企业。 ...